# RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

> **NCT05933044** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 662 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05933044
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-19
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933044, "RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05933044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*